Immuno-oncology

Immuno-oncology represents one of the most transformative therapeutic opportunities in cancer treatment, harnessing the power of the immune system to fight malignancies across multiple tumor types. However, this revolutionary approach brings unique challenges that demand tailored, specialized laboratory expertise and sophisticated biomarker testing strategies.

The complexity of immune checkpoint pathways, tumor microenvironment interactions, and patient-specific immune responses requires comprehensive testing for PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI), and mismatch repair deficiency (dMMR) status. Each are critical for predicting treatment response and optimizing patient selection.

Finding the right laboratory partner becomes essential for navigating the intricate landscape of immuno-oncology biomarker detection, where precision in PD-L1 scoring, advanced sequencing capabilities, and expertise in immune profiling can determine the success or failure of groundbreaking therapies.

Our specialists support the full spectrum of immuno-oncology studies from discovery through phase III registration trials, providing the advanced testing capabilities and regulatory expertise necessary for unlocking the therapeutic potential of immunotherapy.

Biomarker assay development is essential for immuno-oncology research success, with precise detection of PD-L1, tumor mutational burden (TMB), microsatellite instability (MSI), and mismatch repair deficiency (dMMR) requiring validated, customized laboratory solutions that can be deployed globally across clinical development phases. 

The dynamic nature of immune responses and the heterogeneity of tumor microenvironments present unique testing challenges that demand expertise across multiple platforms, from advanced immunohistochemistry for PD-L1 scoring with validated clones (22C3, SP142, SP263) to next-generation sequencing for TMB assessment and molecular testing for MSI-H/dMMR status. 

Understanding which biomarkers to test, when to test them, and how to interpret results within the context of specific tumor types becomes crucial for immuno-oncology success, requiring laboratory partners with deep expertise in immune profiling and regulatory compliance.

Here’s how our testing capabilities support your immuno-oncology trials:

1.NCCN guidelines 2024; 2.Bebb et al. Curr Oncol 2021; *Cerba Research Data In-house mostly available through the ACTOnco®/Cerba France/Cerba US NGS panels or CR Montpellier (IHC) or Cerba France (FISH); IHC=immunohistochemistry; NGS=next-generation sequencing; FISH=fluorescence in situ hybridization; CEA=carcinoembryonic antigen determination; TMB=tumor mutation burden; MSI=microsatellite instability; dMMR= mismatch repair deficient

This comprehensive biomarker landscape in immuno-oncology requires seamless integration of IHC, NGS, and specialized immune assays to provide the complete molecular and immunological picture needed for precision immunotherapy decisions across multiple cancer types.